Our Story

Pharmiva is an innovation driven company with a focus on diseases related to women’s health. We develop and market products based on a unique expert knowledge within research and development of medical products aimed for local administration. We’re committed to reducing the threat of developing bacterial tolerance to antibiotics by offering alternative treatment methods.

In the University town Lund in Sweden, at adjacent specialized lab facilities, we develop, and market patented medical products focused on Women’s Health. Pharmiva has a quality management system that fulfills the requirements of SS-EN ISO 13485:2016 with respect to design, production, marketing and sales of medical products for women’s health.

The Problem

Intimate infections are common among fertile women with associated symptoms like itching, malodor and vaginal discharge. Intimate problems touch all aspects of everyday life, impacting quality of life and may cause women to feel socially stigmatized. There’s also the risk of long-term effects, leading to complications regarding fertility and pregnancies. Today, intimate bacterial infections are treated with antibiotics. Meanwhile, lifetime of antibiotics is diminishing due to accelerating antimicrobial resistance.

Our Soloution

Our patented technology platform Venerol® is based on naturally occurring substances already present in the vaginal flora. Thus, Venerol® diminishes the risk of developing antimicrobial resistance, while re-enforcing the body’s own natural defense system.

Short-term, our primary focus is launching a multifaceted product against intimate infections in women. However, the technology platform itself offers a wider potential and product portfolio.

Our first clinical study, conducted in Sweden on 30 patients diagnosed with bacterial vaginosis, showed promising microbiological and clinical results, meriting major possibilities in further development and commercialization.

Our Focus

We develop and market products based on unique expert knowledge within research and development of medical products for local administration. Our main focus are the following indications:

Vulvovaginal Candida (VVC)

An estimated 75% of all women will experience at least one symptomatic episode during their lifetime.

6 to 9% will experience chronic recurrent candida.

Bacterial Vaginosis (BV)

About 30% of all fertile women are affected by bacterial vaginosis.

Half of them are suffering from symptoms related to the infection.

Sexual Transmitted Infections (STIs)

More than 1 million STIs are acquired every day worldwide.

Key Personnel

Solid experience developing medical products • Specializing in dermatology and drug delivery • C. 20 products in market or previously in market • More than 40 approved patents
Anna Holmberg
Anna Holmberg
Design & Development Manager
Lars Hedbys
Lars Hedbys
Chief Executive Officer
Eva Ståhl Wernersson
Eva Ståhl Wernersson
Quality and Regulatory Manager
Susanna Liljedahl
Susanna Liljedahl
Production Manager
Marie Bolin
Marie Bolin
International Brand Manager
Agneta Runduist
Agneta Runduist
Finance Manager
Åke Lindahl
Åke Lindahl
Intellectual Property Manager
Anders Toft
Anders Toft
External consultant Medical Affairs and Clinical Development
David Sagna
David Sagna
Advisor Design and Development

Board of Directors

Pharmiva
Åke Lindahl

Åke Lindahl

Chairman of the board

David Sagna

David Sagna

Board Member

Karin Bryder

Karin Bryder

Board member

John Moll

John Moll

Board Member

Jens Hansson

Jens Hansson

Board Member

Malte Zaunders

Malte Zaunders

Board Member

Agneta Rundquist

Agneta Rundquist

Adjunct Board Member

Lars Hedbys

Lars Hedbys

Adjunct Board Member

Medical Innovations in Women’s Health